The focus of the Human Imaging Core (Director: Dr. Bradley Erickson) is to provide critical human imaging capabilities to MTPC investigators and extended national and international faculty by making a variety of services available. These include imaging protocol development; image transfer, management and storage; volumetric and other quantitative analysis (cyst distribution, cyst parenchyma-surface area, Dual energy CT) and advanced MR imaging analysis (renal blood flow measurements, intracranial aneurysm detection, and MR elastography) of affected organs in ADPKD. During the past grant cycle to date, the Human Imaging Core has provided image analysis for six NIH, two PKD Foundation, five industry, and three Mayo funded clinical studies or trials. These include volumetric analysis of 2,669 CT and 2,434 MR scans of kidneys or livers, in addition to MR measurements of RBF and other image analyses in a smaller number of patients. The volumetric analysis alone has taken approximately 5,613 hours. The Human Imaging Core has also assisted in the design and management of MR images from Mayo patients with ADPKD participating in multicenter clinical trials (CRISP and HALT) and the protocol development for DIPAK 1 (a clinical trial of Lanreotide supported by the Dutch Kidney Foundation and IPSEN Pharmaceutica). In addition, six new core services that were developed during the prior period: automated kidney segmentation from stereology, image-based classification of patients, magnetic resonance elastography, dual energy CT to characterize renal stones, renal blood flow, cyst- parenchyma surface area, are now available to researchers. Furthermore, the Human Imaging Core actively develops new technologies to enhance the breadth of offerings or the value of the current services. Technologies under development include: novel imaging methods for characterizing PKD (magnetization transfer imaging, diffusion, and blood-oxygen level determination) and differentiating cysts and parenchymal tissues. In addition to providing the services, the core offers training in these techniques. The core has educated and trained a large number of individuals from across the world on the proper use of tools to measure TKV and has also shared some of our algorithms developed in the past grant cycle. For these reasons, we believe that the Human Imaging Core is a critical resource for the study of PKD, and is a unique strength of the current application, as no other PKD Center has such a core.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK090728-06
Application #
8972874
Study Section
Special Emphasis Panel (ZDK1-GRB-G (M5))
Project Start
Project End
Budget Start
2015-09-15
Budget End
2016-06-30
Support Year
6
Fiscal Year
2015
Total Cost
$271,621
Indirect Cost
$100,790
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699
Masyuk, Tatyana V; Masyuk, Anatoliy I; LaRusso, Nicholas F (2018) Polycystic liver disease: The interplay of genes causative for hepatic and renal cystogenesis. Hepatology 67:2462-2464
Cornec-Le Gall, Emilie; Olson, Rory J; Besse, Whitney et al. (2018) Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet 102:832-844
He, Kai; Ma, Xiaoyu; Xu, Tao et al. (2018) Axoneme polyglutamylation regulated by Joubert syndrome protein ARL13B controls ciliary targeting of signaling molecules. Nat Commun 9:3310
Idowu, Jessica; Home, Trisha; Patel, Nisha et al. (2018) Aberrant Regulation of Notch3 Signaling Pathway in Polycystic Kidney Disease. Sci Rep 8:3340
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Brosnahan, Godela M; Abebe, Kaleab Z; Moore, Charity G et al. (2018) Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis 71:666-676
Besse, Whitney; Choi, Jungmin; Ahram, Dina et al. (2018) A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Hum Mutat 39:378-382
Masyuk, Anatoliy I; Masyuk, Tatyana V; Lorenzo Pisarello, Maria J et al. (2018) Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. Hepatology 67:1088-1108
Lakhia, Ronak; Yheskel, Matanel; Flaten, Andrea et al. (2018) PPAR? agonist fenofibrate enhances fatty acid ?-oxidation and attenuates polycystic kidney and liver disease in mice. Am J Physiol Renal Physiol 314:F122-F131

Showing the most recent 10 out of 192 publications